---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-26-000053"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2026-08-13T20:07:54+00:00"
generated_at: "2026-08-13T20:10:10.664835+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Caribou Q2 2026 net loss $24.3M; vispa-cel and CB-011 show strong efficacy data

## Summary
- Q2 2026 net loss $24.3M ($0.24/share) vs $54.1M ($0.58) in Q2 2025, which included $21.3M impairment.
- Revenue $1.5M vs $2.7M; R&D $18.9M vs $27.7M; G&A $7.9M vs $10.4M.
- Cash $113.8M at June 30, 2026, expected to fund operations to end of 2027.
- ANTLER data: 82% ORR, 67% CR, 17.1-month median PFS in 2L LBCL (N=27) for vispa-cel.
- CB-011 CaMMouflage: 92% ORR, 83% ≥CR, 91% MRD negativity; initial dose expansion data expected H2 2026.

## SEC filing metadata
- accession: 0001619856-26-000053
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2026-08-13T20:07:54+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000053/0001619856-26-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000053/crbu-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-26-000053
- JSON: https://secwatch.observer/filing/0001619856-26-000053.json
- Plain text: https://secwatch.observer/filing/0001619856-26-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.